We are delighted to announce the selection of the c4c consortium’s first portfolio of pan-European paediatric studies aimed at advancing the understanding of high priority medicines commonly used in babies, children and young people in Europe. The four inaugural studies will be conducted by academic institutions, in addition to three or four studies by industry…
DetailsThe c4c consortium has issued a call for tender for subcontracting a specialised business school or company that can assist in the development of a sustainable business model for a pan-European paediatric clinical trials network. An important element of c4c is the push for a well-functioning business model and long-term sustainability, making sure that the network will continue to assume its pivotal…
DetailsThe European Medicines Agency (EMA) has recently published a booklet covering the process undertaken for medicines for human use and which are authorised through the EU centralised procedure. With a user-friendly layout, it communicates the steps that are taken from the initial research stages of a new medicine to when it is eventually marketed to…
DetailsWe are now seeking experts interested to be part of Clinical or Methodology Expert Groups and who want to contribute at providing advice. One task of the c4c consortium is to deliver the scientific feasibility advice needed to improve child health and paediatric medicine development. Groups of experts (methodological, clinical, and parents/patients) will be set up to provide…
DetailsThe countdown has begun to Rare Disease Day 2019 on 28th February. People around the world are joining the global movement for rare diseases by taking part in the #ShowYourRare campaign, holding events and raising awareness. There are over 6,000 rare diseases. The European Union considers a disease as rare when it affects less than 1 in 2,000…
Details
